Protein Inhibitors - RSV604 (CAS: 676128-63-5)

Location：Home > Biochemicals > Protein Inhibitors

RSV604 (CAS: 676128-63-5)

Catalog #：EBC51027

RSV604 (CAS: 676128-63-5)

SKU-Pack Size	Availability	Size	Price
EBC51027-1ML	In Stock	1mL(10mM in DMSO)	$148.50
EBC51027-2MG	In Stock	2mg	$88.50
EBC51027-5MG	In Stock	5mg	$118.50
EBC51027-10MG	In Stock	10mg	$193.50
EBC51027-50MG	In Stock	50mg	$748.50

If you want to get a larger packsize, Please contact your local distributor or
email us atinfo@ebiocell.com

Please Select The Country You Are In To Find Your Local Distributor.

	EbioCell	Phone：(540) 808-3925
	Imperial Business Park 4819 Emperor Boulevard,	E-mail：order@ebiocell.com
United States	Suite 408 Durham, NC 27703, USA	Web：www.ebiocell.com

Product Information

Synonym(s)

RSV-604，RSV 604

Application

RSV604 is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM)

CAS Number

676128-63-5

Purity

≥98.0%

Molecular Weight

388.39

Molecular Formula

C₂₂H₁₇FN₄O₂

SMILES

C1=CC=C(C=C1)C2=N[C@@H](C(=O)NC3=CC=CC=C32)NC(=O)NC4=CC=CC=C4F

Target & IC50

RSV:EC50 = 0.86 μM

Solubility

DMSO: 195 mg/mL (502.07 mM)
Ethanol: 9 mg/mL (23.17 mM)

Preparing Stock Solutions

ConcentrationSolventMass	1 mg	5 mg	10 mg
1 mM	2.5747 ml	12.8737 ml	25.7473 ml
5 mM	0.5149 ml	2.5747 ml	5.1495 ml
10 mM	0.2575 ml	1.2874 ml	2.5747 ml
50 mM	0.0515 ml	0.2575 ml	0.5149 ml

Shipping

Gel Pack

Storage

Store at -20°C

Research Use

For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use.

Product Description

RSV604 is a novel inhibitor of respiratory syncytial virus replication(EC50=0.86 uM); a putative RSV nucleoprotein(N) inhibitor in phase 2 clinical trials.IC50 value: 0.86 uM(EC50) It proved to be equipotent against all clinical isolates tested of both the A and B subtypes of the virus. The compound has a low rate of in vitro resistance development. Sequencing revealed that the resistant virus had mutations within the nucleocapsid protein. This is a novel mechanism of action for anti-RSV compounds. In a three-dimensional human airway epithelial cell model, RSV604 was able to pass from the basolateral side of the epithelium effectively to inhibit virus replication after mucosal inoculation. RSV604, which is currently in phase II clinical trials, represents the first in a new class of RSV inhibitors and may have significant potential for the effective treatment of RSV disease.

Specific Protocols

>>	Western Blotting Protocol	>>	Immunoprecipitation Protocol
>>	Immunohistochemistry Protocol	>>	Immunofluorescence Protocol
>>	Immunocytochemistry Protocol	>>	Flow Cytometry Protocol
>>	ChIP Protocol	>>	ELISA Protocol
>>	HPLC Protocol	>>	PCR Protocol